Vitiligo patients experience barriers in accessing care.

Vitiligo is a loss of pigment occurring in approximately 0.4% to 2% of the worldwide population. The aim of this study was to determine and characterize barriers to access of care in US patients with vitiligo.

Efficacy and safety of ustekinumab in adolescents.

The biologic agent ustekinumab is a human monoclonal antibody that binds to the p40 subunit shared by interleukins (ILs) 12 and 23. The antibody is able to prevent binding of cytokines to the IL-12Rβ1 cell surface receptor and therefore may prevent IL-23 driven activation of the IL-23/Th 17 axis of inflammation. The anti-inflammatory activity has been beneficial in adult psoriasis.

Phototherapy for atopic dermatitis.

Phototherapy is a second-line treatment for moderate to severe atopic dermatitis (AD) that effectively decreases cutaneous inflammation with minimal or no systemic side effects. Children in grade school, adolescents, and adults may benefit from phototherapy, when they have chronic AD refractory to first-line topical treatments. This review focuses on six approaches for phototherapy in AD: (1) broadband ultraviolet B (UVB), (2) Goeckerman regimen (coal tar + broadband UVB), (3) narrowband UVB, (4) excimer lasers for targeted areas, (5) combination UVA/UVB, and (6) UVA-1.

A practical overview of pediatric atopic dermatitis, part 3: differential diagnosis, comorbidities, and measurement of disease burden.

Atopic dermatitis (AD) is a multisystem disorder that has wide-reaching comorbidities and may mimic a variety of skin conditions. In the third part of this series, the differential diagnosis of pediatric AD including possible clinical mimics is discussed as well as the many recently identified comorbidities of pediatric AD, including psychosocial and allergic diseases.

A Practical Approach to the Diagnosis and Treatment of Vitiligo in Children.

Vitiligo is a common inflammatory skin disease with a worldwide prevalence of 0.5% to 2.0% of the population.

A practical overview of pediatric atopic dermatitis, part 1: epidemiology and pathogenesis.

Atopic dermatitis (AD) is a multisystem inflammatory disorder that is part of the spectrum of atopy, a series of conditions in which hyperreactivity and allergic symptoms are triggered by a series of causes including environmental allergens and irritants. Atopic dermatitis affects approximately one-quarter of children in developed countries and can have a negative impact on quality of life. In part 1 of this series addressing AD, the epidemiology and pathogenesis of AD are reviewed with an overview of skin barrier function.

Diet and atopic dermatitis.

Dermatologists and pediatric dermatologists frequently treat patients with atopic dermatitis (AD), and patients and guardians often associate AD with food allergies. A common misconception is that dietary restrictions will resolve the disease. The role of diet is evolving in the discussion of AD.

Assessment of atopic dermatitis using self-report and caregiver report: a multicentre validation study.

Background: The epidemiology of atopic dermatitis (AD) in the U.S.A.

Complementary and alternative medicines and childhood eczema: a US population-based study.

The prevalence of complementary and alternative medicine (CAM) use in US children with eczema is unknown. Furthermore, it is unknown whether CAM use in the United States is associated with higher eczema prevalence. We sought to determine the eczema prevalence in association with CAM usage.

Pediatric dermatology training survey of United States dermatology residency programs.

Variability exists in pediatric dermatology education for dermatology residents. We sought to formally assess the pediatric dermatology curriculum and experience in a dermatology residency program. Three unique surveys were developed for dermatology residents, residency program directors, and pediatric dermatology fellowship program directors.

Antiphospholipid antibody syndrome secondary to trimethoprim/sulfamethoxazole.

Antiphospholipid antibody syndrome (APS) results from autoantibodies to cell surface phospholipids or phospholipid-binding proteins resulting in clotting anomalies and can have devastating sequelae, including stroke, deep venous thrombosis, pulmonary embolism, and recurrent spontaneous abortions. However, cutaneous manifestations are the first sign of APS in up to 41% of patients. We present a case report of APS that developed several days after taking trimethoprim/sulfamethoxazole.

Adjunctive trichloroacetic acid therapy enhances squaric acid response to verruca vulgaris.

Squaric acid dibutyl ester (SADBE) is a commonly used treatment for verruca vulgaris of childhood. Few studies, however, have examined the role of SADBE in combination with other topical therapies for warts. We sought to determine if trichloroacetic acid 50% (TCA) and/or cantharidin 0.